Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2018 (2018), Article ID 2438598, 18 pages
https://doi.org/10.1155/2018/2438598
Research Article

Natural Killer Cells from Malignant Pleural Effusion Are Endowed with a Decidual-Like Proangiogenic Polarization

1Vascular Biology and Angiogenesis Laboratory, Scientific and Technology Pole, IRCCS MultiMedica, Milano, Italy
2Immunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy
3Department of Medicine and Surgery, University of Insubria, Varese, Italy

Correspondence should be addressed to Douglas M. Noonan; ti.airbusninu@nanoon.salguod

Received 6 October 2017; Accepted 19 December 2017; Published 29 March 2018

Academic Editor: Cinzia Fionda

Copyright © 2018 Annalisa Bosi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Montaldo, P. Vacca, C. Vitale et al., “Human innate lymphoid cells,” Immunology Letters, vol. 179, pp. 2–8, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Spits and T. Cupedo, “Innate lymphoid cells: emerging insights in development, lineage relationships, and function,” Annual Review of Immunology, vol. 30, no. 1, pp. 647–675, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Vivier, E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini, “Functions of natural killer cells,” Nature Immunology, vol. 9, no. 5, pp. 503–510, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Bruno, A. Pagani, L. Pulze et al., “Orchestration of angiogenesis by immune cells,” Frontiers in Oncology, vol. 4, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Ferlazzo, D. Thomas, S. L. Lin et al., “The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic,” Journal of Immunology, vol. 172, no. 3, pp. 1455–1462, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. D. M. Noonan, A. de Lerma Barbaro, N. Vannini, L. Mortara, and A. Albini, “Inflammation, inflammatory cells and angiogenesis: decisions and indecisions,” Cancer Metastasis Reviews, vol. 27, no. 1, pp. 31–40, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Santoni, A. Zingoni, C. Cerboni, and A. Gismondi, “Natural killer (NK) cells from killers to regulators: distinct features between peripheral blood and decidual NK cells,” American Journal of Reproductive Immunology, vol. 58, no. 3, pp. 280–288, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Vivier, D. H. Raulet, A. Moretta et al., “Innate or adaptive immunity? The example of natural killer cells,” Science, vol. 331, no. 6013, pp. 44–49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. M. A. Degli-Esposti and M. J. Smyth, “Close encounters of different kinds: dendritic cells and NK cells take centre stage,” Nature Reviews Immunology, vol. 5, no. 2, pp. 112–124, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Trinchieri, “Biology of natural killer cells,” Advances in Immunology, vol. 47, pp. 187–376, 1989. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Moretta, F. Locatelli, and L. Moretta, “Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias,” Immunological Reviews, vol. 224, no. 1, pp. 58–69, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. Cooper, T. A. Fehniger, and M. A. Caligiuri, “The biology of human natural killer-cell subsets,” Trends in Immunology, vol. 22, no. 11, pp. 633–640, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Laroni, E. Armentani, N. Kerlero de Rosbo et al., “Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis,” Journal of Autoimmunity, vol. 72, pp. 8–18, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Morandi, A. L. Horenstein, A. Chillemi et al., “CD56brightCD16 NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting autologous CD4+ T cell proliferation,” Journal of Immunology, vol. 195, no. 3, pp. 965–972, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. J. S. Schleypen, M. von Geldern, E. H. Weiß et al., “Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes,” International Journal of Cancer, vol. 106, no. 6, pp. 905–912, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Hanna, D. Goldman-Wohl, Y. Hamani et al., “Decidual NK cells regulate key developmental processes at the human fetal-maternal interface,” Nature Medicine, vol. 12, no. 9, pp. 1065–1074, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Vacca, L. Moretta, A. Moretta, and M. C. Mingari, “Origin, phenotype and function of human natural killer cells in pregnancy,” Trends in Immunology, vol. 32, no. 11, pp. 517–523, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Chaouat, N. Ledée-Bataille, K. B. Chea, and S. Dubanchet, “Cytokines and implantation,” Chemical Immunology and Allergy, vol. 88, pp. 34–63, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Chaouat, N. Ledee-Bataille, and S. Dubanchet, “Immune cells in uteroplacental tissues throughout pregnancy: a brief review,” Reproductive Biomedicine Online, vol. 14, no. 2, pp. 256–266, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. S. M. Blois, B. F. Klapp, and G. Barrientos, “Decidualization and angiogenesis in early pregnancy: unravelling the functions of DC and NK cells,” Journal of Reproductive Immunology, vol. 88, no. 2, pp. 86–92, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Bruno, G. Ferlazzo, A. Albini, and D. M. Noonan, “A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis,” JNCI: Journal of the National Cancer Institute, vol. 106, no. 8, article dju200, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. F. R. Balkwill, M. Capasso, and T. Hagemann, “The tumor microenvironment at a glance,” Journal of Cell Science, vol. 125, no. 23, pp. 5591–5596, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Sica and A. Mantovani, “Macrophage plasticity and polarization: in vivo veritas,” The Journal of Clinical Investigation, vol. 122, no. 3, pp. 787–795, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Bruno, C. Focaccetti, A. Pagani et al., “The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer,” Neoplasia, vol. 15, no. 2, pp. 133–IN7, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Baginska, E. Viry, J. Paggetti et al., “The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity,” Frontiers in Immunology, vol. 4, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Hasmim, Y. Messai, L. Ziani et al., “Critical role of tumor microenvironment in shaping NK cell functions: implication of hypoxic stress,” Frontiers in Immunology, vol. 6, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Vacca, S. Martini, V. Garelli, G. Passalacqua, L. Moretta, and M. C. Mingari, “NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation,” European Journal of Immunology, vol. 43, no. 2, pp. 550–561, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Alter, J. M. Malenfant, and M. Altfeld, “CD107a as a functional marker for the identification of natural killer cell activity,” Journal of Immunological Methods, vol. 294, no. 1-2, pp. 15–22, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Vacca, S. Martini, M. C. Mingari, and L. Moretta, “NK cells from malignant pleural effusions are potent antitumor effectors,” Oncoimmunology, vol. 2, no. 4, article e23638, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. C. M. Nielsen, M. J. White, M. R. Goodier, and E. M. Riley, “Functional significance of CD57 expression on human NK cells and relevance to disease,” Frontiers in Immunology, vol. 4, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. F. Borrego et al., “CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor,” Immunology, vol. 97, no. 1, pp. 159–165, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. J. E. Heffner, “Management of the patient with a malignant pleural effusion,” Seminars in Respiratory and Critical Care Medicine, vol. 31, no. 06, pp. 723–733, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Karpathiou, D. Stefanou, and M. E. Froudarakis, “Pleural neoplastic pathology,” Respiratory Medicine, vol. 109, no. 8, pp. 931–943, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Novello, C. Pinto, V. Torri et al., “The third Italian consensus conference for malignant pleural mesothelioma: state of the art and recommendations,” Critical Reviews in Oncology/Hematology, vol. 104, pp. 9–20, 2016. View at Publisher · View at Google Scholar · View at Scopus
  36. H. H. Popper, “Progression and metastasis of lung cancer,” Cancer Metastasis Reviews, vol. 35, no. 1, pp. 75–91, 2016. View at Publisher · View at Google Scholar · View at Scopus
  37. J. M. Porcel, J. P. Diaz, and D. S. Chi, “Clinical implications of pleural effusions in ovarian cancer,” Respirology, vol. 17, no. 7, pp. 1060–1607, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. T. S. Singer, A. Sulkes, and S. Biran, “Pleural effusion in breast cancer: influence upon clinical course and survival,” Chemioterapia, vol. 5, no. 1, pp. 66–69, 1986. View at Google Scholar
  39. G. T. Stathopoulos and I. Kalomenidis, “Malignant pleural effusion: tumor-host interactions unleashed,” American Journal of Respiratory and Critical Care Medicine, vol. 186, no. 6, pp. 487–492, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Pace, L. Siena, M. Ferraro et al., “Role of prostaglandin E2 in the invasiveness, growth and protection of cancer cells in malignant pleuritis,” European Journal of Cancer, vol. 42, no. 14, pp. 2382–2389, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Giarnieri, G. Bellipanni, M. Macaluso et al., “Review: cell dynamics in malignant pleural effusions,” Journal of Cellular Physiology, vol. 230, no. 2, pp. 272–277, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Zitvogel, A. Tesniere, and G. Kroemer, “Cancer despite immunosurveillance: immunoselection and immunosubversion,” Nature Reviews Immunology, vol. 6, no. 10, pp. 715–727, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. S. M. Mahmoud, E. C. Paish, D. G. Powe et al., “Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer,” Journal of Clinical Oncology, vol. 29, no. 15, pp. 1949–1955, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. F. Pages, A. Kirilovsky, B. Mlecnik et al., “In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 5944–5951, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. M. L. Ascierto, M. O. Idowu, Y. Zhao et al., “Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients,” Journal of Translational Medicine, vol. 11, no. 1, p. 145, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Mamessier, A. Sylvain, M. L. Thibult et al., “Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity,” The Journal of Clinical Investigation, vol. 121, no. 9, pp. 3609–3622, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. S. Rocca, M. P. Roberti, J. M. Arriaga et al., “Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients,” Innate Immunity, vol. 19, no. 1, pp. 76–85, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. P. Carrega, B. Morandi, R. Costa et al., “Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56brightCD16 cells and display an impaired capability to kill tumor cells,” Cancer, vol. 112, no. 4, pp. 863–875, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. F. J. Culley, “Natural killer cells in infection and inflammation of the lung,” Immunology, vol. 128, no. 2, pp. 151–163, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. P. Carrega, I. Bonaccorsi, E. di Carlo et al., “CD56brightperforinlow noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph,” Journal of Immunology, vol. 192, no. 8, pp. 3805–3815, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. B. V. Dons'koi, V. P. Chernyshov, and D. V. Osypchuk, “Measurement of NK activity in whole blood by the CD69 up-regulation after co-incubation with K562, comparison with NK cytotoxicity assays and CD107a degranulation assay,” Journal of Immunological Methods, vol. 372, no. 1-2, pp. 187–195, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Kaczmarek and J. Sikora, “Macrophages in malignant pleural effusions - alternatively activated tumor associated macrophages,” Współczesna Onkologia, vol. 4, no. 4, pp. 279–284, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Yang, F. Wang, L. Wang et al., “CD163+ tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients,” Oncotarget, vol. 6, no. 12, pp. 10592–10603, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. F. Wang, L. Yang, Q. Gao et al., “CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion,” Cancer Immunology, Immunotherapy, vol. 64, no. 8, pp. 965–976, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. L. A. Lievense, R. Cornelissen, K. Bezemer, M. E. H. Kaijen-Lambers, J. P. J. J. Hegmans, and J. G. J. V. Aerts, “Pleural effusion of patients with malignant mesothelioma induces macrophage-mediated T cell suppression,” Journal of Thoracic Oncology, vol. 11, no. 10, pp. 1755–1764, 2016. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Li, L. Yang, L. Wang et al., “Impaired T cell function in malignant pleural effusion is caused by TGF-β derived predominantly from macrophages,” International Journal of Cancer, vol. 139, no. 10, pp. 2261–2269, 2016. View at Publisher · View at Google Scholar · View at Scopus
  57. J. J. Sikora, G. T. Dworacki, M. T. Kaczmarek, R. E. Jenek, and J. O. Żeromski, “Immunosuppressive mechanisms in the microenvironment of malignant pleural effusions,” Cancer Detection and Prevention, vol. 28, no. 5, pp. 325–330, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. D. S. Allan, B. Rybalov, G. Awong et al., “TGF-β affects development and differentiation of human natural killer cell subsets,” European Journal of Immunology, vol. 40, no. 8, pp. 2289–2295, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. D. B. Keskin, D. S. J. Allan, B. Rybalov et al., “TGFβ promotes conversion of CD16+ peripheral blood NK cells into CD16− NK cells with similarities to decidual NK cells,” Proceedings of the National Academy of Sciences, vol. 104, no. 9, pp. 3378–3383, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. A. S. Cerdeira, A. Rajakumar, C. M. Royle et al., “Conversion of peripheral blood NK cells to a decidual NK-like phenotype by a cocktail of defined factors,” Journal of Immunology, vol. 190, no. 8, pp. 3939–3948, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. K. C. Conlon, E. Lugli, H. C. Welles et al., “Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer,” Journal of Clinical Oncology, vol. 33, no. 1, pp. 74–82, 2015. View at Publisher · View at Google Scholar · View at Scopus
  62. E. Vacchelli, F. Aranda, N. Bloy et al., “Trial watch—immunostimulation with cytokines in cancer therapy,” Oncoimmunology, vol. 5, no. 2, article e1115942, 2016. View at Publisher · View at Google Scholar · View at Scopus
  63. D. Gotthardt, E. M. Putz, E. Grundschober et al., “STAT5 is a key regulator in NK cells and acts as a molecular switch from tumor surveillance to tumor promotion,” Cancer Discovery, vol. 6, no. 4, pp. 414–429, 2016. View at Publisher · View at Google Scholar · View at Scopus
  64. D. Gotthardt and V. Sexl, “STATs in NK-cells: the good, the bad, and the ugly,” Frontiers in Immunology, vol. 7, 2017. View at Publisher · View at Google Scholar · View at Scopus
  65. J. W. Leong, J. M. Chase, R. Romee et al., “Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells,” Biology of Blood and Marrow Transplantation, vol. 20, no. 4, pp. 463–473, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. K. Pilipow, A. Roberto, M. Roederer, T. A. Waldmann, D. Mavilio, and E. Lugli, “IL15 and T-cell stemness in T-cell-based cancer immunotherapy,” Cancer Research, vol. 75, no. 24, pp. 5187–5193, 2015. View at Publisher · View at Google Scholar · View at Scopus